Established Cardiovascular Disease: Emerging Mechanism Research
Established cardiovascular disease (CVD) here means atherosclerotic disease that has already produced a clinical event or diagnosis: prior myocardial infarction, stroke, peripheral artery disease, or angiographically confirmed coronary disease. This is a secondary-prevention population, distinct from people being screened for future risk. The drugs and biology discussed below apply to patients already on, or being considered for, guideline-directed medical therapy (statins, antiplatelet agents, blood pressure control), not to primary prevention decisions.
The direct answer: lowering LDL cholesterol with statins and, where indicated, PCSK9 inhibitors reduces cardiovascular events but does not eliminate them. Large outcomes trials have identified other biologically distinct drivers of residual risk in people already on optimal lipid-lowering therapy, including vascular inflammation (IL-1β/IL-6/NLRP3 signaling), clonal hematopoiesis, gut-microbiome-derived metabolites such as TMAO, and elevated lipoprotein(a). Some of these pathways now have trial-tested interventions (colchicine, GLP-1 receptor agonists); others (CHIP screening, Lp(a)-lowering siRNA drugs) remain investigational or pending outcome data. This is trial and observational evidence, not a guideline mandate to test or treat every pathway in every patient.
Why LDL control is necessary but not sufficient
Statins and PCSK9 inhibitors lower LDL cholesterol substantially, and lower LDL is causally linked to fewer cardiovascular events. But even in trials with near-maximal LDL suppression, a meaningful share of patients still experience a heart attack, stroke, or cardiovascular death during follow-up. That gap is what researchers call residual risk, and it has redirected attention toward mechanisms that operate independently of cholesterol: chronic low-grade inflammation, somatic mutations in blood stem cells, microbial metabolites produced in the gut, and genetically fixed lipoprotein particles that statins do not touch.
Elevated high-sensitivity C-reactive protein (hsCRP) despite statin therapy has been used in research settings as a marker of this residual inflammatory risk. The general finding, replicated across multiple statin-trial cohorts, is that a substantial proportion of statin-treated patients still have hsCRP above the threshold associated with ongoing plaque activity. Exact prevalence figures vary by cohort and should be checked against the specific trial publication before being quoted as a fixed number.
Is targeting inflammation directly useful, and for whom?
This is the pathway with the strongest randomized-trial support outside of lipid lowering.
Canakinumab (CANTOS). A large randomized trial in post-myocardial-infarction patients tested canakinumab, a monoclonal antibody against interleukin-1β, against placebo on top of standard therapy. The trial reported a reduction in major adverse cardiovascular events (MACE) that was independent of any change in LDL cholesterol, which was the first randomized proof that inflammation is a causal driver of atherosclerotic events and not merely a bystander marker. Canakinumab itself was not brought to market for cardiovascular disease, in part because of infection risk and cost.
Colchicine. Two separate randomized trials, one enrolling patients within 30 days of a myocardial infarction and one enrolling patients with chronic stable coronary disease, both reported reductions in cardiovascular events with low-dose colchicine (0.5 mg daily) versus placebo. The consistency of direction across an acute-post-MI population and a chronic stable population is the reason colchicine has moved into some clinical guideline discussions as a secondary-prevention option, generally reserved for patients with recurrent events despite standard therapy or intolerance to other options. Colchicine has gastrointestinal side effects and dose-dependent hematologic and hepatic toxicity, and drug interactions (notably with statins and some antibiotics) matter clinically. Exact effect sizes and confidence intervals from these trials should be verified against the original publications before being used in a comparison table or patient-facing claim.
NLRP3 and IL-6. Mechanistically, cholesterol crystals and oxidized LDL activate the NLRP3 inflammasome inside macrophages, which processes interleukin-1β into its active form; IL-1β then drives IL-6 and downstream CRP production. Because IL-1β signals partly through IL-6, direct IL-6 blockade (for example, ziltivekimab) has been tested in early-phase trials in patients with chronic kidney disease and elevated hsCRP, with encouraging reductions in inflammatory markers. Whether IL-6 blockade reduces hard cardiovascular events is not yet established; that requires a dedicated outcomes trial, which was ongoing as of the most recent published phase 2 data.
Does clonal hematopoiesis (CHIP) change cardiovascular risk, and should anyone be tested for it?
Clonal hematopoiesis of indeterminate potential describes age-related somatic mutations in blood stem cells, most often in DNMT3A, TET2, ASXL1, or JAK2, that let a single mutant clone expand and populate a growing share of a person's blood cells. Landmark cohort and genetic studies have linked CHIP carriage to a meaningfully higher risk of coronary heart disease and ischemic stroke, independent of traditional risk factors, and TET2-mutant macrophages in particular appear to overproduce IL-1β and IL-6 through NLRP3 hyperactivation, tying CHIP directly to the inflammatory pathway above.
This is observational and mechanistic evidence, not an established clinical pathway. There is no cardiology society guideline recommending routine CHIP screening, and no completed prospective trial has shown that identifying CHIP and intervening on it changes cardiovascular outcomes. CHIP sequencing outside of hematology or oncology workups is currently a research tool. A patient with unexplained early or recurrent coronary disease despite optimal therapy might reasonably ask a cardiologist whether a clinical trial involving CHIP testing is available, but this is not something to pursue as routine care.
Does the TMAO pathway matter for diet and drug choices?
Gut bacteria convert dietary phosphatidylcholine and L-carnitine (found in red meat and eggs) into trimethylamine, which the liver oxidizes into trimethylamine N-oxide (TMAO). Observational cohort data have linked higher plasma TMAO to higher MACE risk, and TMAO has plausible mechanisms of harm: platelet hyperreactivity and macrophage cholesterol loading in the vessel wall.
No approved drug targets this pathway in humans. An experimental compound (3,3-dimethyl-1-butanol) that inhibits microbial TMA production has reduced TMAO in animal models, but there is no human outcomes data. What is actionable today is dietary: a Mediterranean-style diet emphasizing olive oil, nuts, vegetables, and reduced red meat has randomized trial evidence (PREDIMED) for reducing cardiovascular events in high-risk adults, and separately, this dietary pattern is known to lower TMAO within weeks. The overlap between these two facts is suggestive, not proof that TMAO reduction is the mechanism behind PREDIMED's benefit; the trial was not designed to isolate that pathway.
Should patients with established CVD get their Lp(a) checked?
Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle whose blood level is set almost entirely by genetics (the LPA gene) and does not respond meaningfully to statins, diet, or exercise. European cardiology guidance has moved toward recommending at least one lifetime Lp(a) measurement per adult to identify people with very high inherited levels, who carry an elevated lifetime risk of atherosclerotic disease comparable in some analyses to heterozygous familial hypercholesterolemia. Readers should confirm the exact wording and threshold in the current guideline document rather than relying on a paraphrase, since specific numeric thresholds are the kind of detail that gets revised between guideline cycles.
There is currently no approved Lp(a)-lowering drug. Two RNA-based agents, an antisense oligonucleotide (pelacarsen) and a small interfering RNA (olpasiran), have produced large reductions in Lp(a) levels in phase 2 trials, and phase 3 outcomes trials are underway or have completed enrollment. Until those outcome trials report, elevated Lp(a) is a risk-stratification finding, not something with a specific drug treatment to prescribe. Knowing a patient's Lp(a) can still inform how aggressively a clinician manages the other, modifiable risk factors.
Do GLP-1 receptor agonists protect the heart independent of weight loss?
GLP-1 receptor agonists were developed for type 2 diabetes and, more recently, obesity, but several large cardiovascular outcomes trials (LEADER with liraglutide, SUSTAIN-6 with semaglutide, and separately a trial in overweight or obese adults with established CVD but without diabetes) have reported reductions in MACE. The reduction in the non-diabetic obesity trial was larger than would be expected from weight loss alone, based on the modest average weight loss observed, which has led researchers to propose direct vascular effects: GLP-1 receptors are expressed on cardiomyocytes, vascular smooth muscle, and macrophages, and preclinical work suggests receptor activation dampens NF-κB-driven inflammatory signaling and reduces endothelial oxidative stress. This mechanistic explanation is plausible but not proven in humans; the outcomes trials show benefit, they do not prove the specific molecular pathway responsible for it.
GLP-1 receptor agonists are FDA-approved for type 2 diabetes and, at higher doses, for chronic weight management; the cardiovascular-risk-reduction indication in people with established CVD and overweight/obesity reflects specific trial populations and should be checked against current FDA labeling for the exact approved population and dose before assuming it applies to a given patient.
What about endothelial dysfunction and allopurinol?
In established CVD, oxidative stress can "uncouple" endothelial nitric oxide synthase (eNOS), turning an enzyme that normally protects vessels into one that generates more oxidative damage, partly through depletion of its cofactor tetrahydrobiopterin (BH4). BH4 supplementation improves endothelial function in small mechanistic studies, but no large outcomes trial has shown it reduces MACE.
Allopurinol, a gout drug that inhibits xanthine oxidase and lowers superoxide production, was a logical candidate to test this pathway. A large randomized trial in patients with ischemic heart disease found no reduction in MACE with allopurinol versus usual care. That null result is informative: reducing one downstream source of oxidative stress, without correcting the upstream drivers, was not enough to change outcomes in this trial population. It argues against extrapolating "antioxidant mechanism" into "cardiovascular benefit" without a dedicated outcomes trial.
Trained immunity and cardiac fibrosis: mechanistic, not yet actionable
Two further areas are active research fronts without a clear clinical action yet.
Trained immunity describes epigenetic reprogramming of monocytes after a triggering event, such as a myocardial infarction, that leaves those cells primed to overreact to a later, unrelated stimulus like a minor infection. This has been observed in monocytes from coronary artery disease patients and is proposed as one reason CVD patients can have disproportionate inflammatory flares after seemingly minor illness. Metformin and mTOR inhibitors reverse trained-immunity phenotypes in preclinical models; whether this translates into a clinical strategy in humans is unestablished.
Cardiac fibrosis, driven by TGF-β signaling that converts fibroblasts into collagen-depositing myofibroblasts after repeated ischemic injury, stiffens the ventricle and creates arrhythmia-prone tissue. Finerenone, a non-steroidal mineralocorticoid receptor antagonist approved for chronic kidney disease with type 2 diabetes, reduced cardiovascular events in a large trial in that population, plausibly through anti-fibrotic effects, though the trial was not designed to isolate fibrosis reduction as the mechanism.
What is established, what is plausible, and what is not proven
- Established by randomized outcomes trials: LDL lowering with statins and PCSK9 inhibitors reduces MACE; targeting IL-1β/IL-6-linked inflammation with canakinumab or colchicine reduces MACE in secondary prevention; GLP-1 receptor agonists reduce MACE in trial populations with diabetes or obesity and established CVD; a Mediterranean dietary pattern reduces MACE in high-risk adults.
- Plausible but not proven in humans: BH4 supplementation, IL-6 blockade for hard cardiovascular outcomes, TMAO-lowering compounds, and reversing trained immunity with metformin/mTOR inhibitors specifically for cardiovascular benefit.
- Not established as clinical practice: routine CHIP screening in cardiology, Lp(a)-lowering drug therapy (no approved agent exists), and using allopurinol for cardiovascular protection (a large trial found no benefit).
Numeric effect sizes, confidence intervals, and exact trial enrollment figures throughout cardiovascular mechanism research are worth confirming against the original trial publication before they are used in a patient conversation or a comparison table; secondhand summaries, including this one, can drift from the primary source over time.
A framework for reading "new heart disease mechanism" news
Patients with established CVD, and the people advising them, are regularly presented with a new mechanism story (inflammation, gut bacteria, a gene mutation, a hormone receptor). Before changing anything about a treatment plan, it helps to ask four questions in order:
| Question | If the answer is favorable | If the answer is unfavorable |
|---|---|---|
| 1. Is there a randomized outcomes trial, or only an observational/mechanistic study? | Randomized trial evidence (e.g., colchicine, GLP-1 receptor agonists) can inform a real conversation with a clinician. | Observational or preclinical evidence (e.g., CHIP, TMAO, trained immunity) should be treated as a research lead, not a treatment cue. |
| 2. Is there an FDA-approved drug for this specific pathway, and for this specific population? | An approved option (e.g., GLP-1 receptor agonists for eligible patients) can be discussed as a real choice, with attention to the approved dose and population. | No approved drug (e.g., Lp(a)-lowering agents, TMAO inhibitors) means the "target" is not yet a treatment, regardless of how strong the mechanism sounds. |
| 3. Does the trial population match this patient? (prior event type, diabetes status, kidney function, age) | A close match supports cautious extrapolation. | A mismatch (e.g., a trial in CKD patients being applied to someone without kidney disease) means the result may not transfer. |
| 4. What does adding this therapy cost in side effects, monitoring, or drug interactions? | Low added burden (e.g., dietary change) is a reasonable next step to discuss. | Meaningful burden (e.g., colchicine's GI and interaction profile, immune-modulating antibodies' infection risk) means the decision needs an individualized risk-benefit conversation with a cardiologist, not a decision from an article. |
This is a general framework for evaluating claims, not a substitute for individualized medical advice, and it does not set a dose or make a diagnosis.
When to seek urgent care rather than research this further
New or worsening chest pain, pain radiating to the arm or jaw, sudden shortness of breath, fainting, or sudden weakness or speech difficulty are reasons to seek emergency evaluation immediately rather than research mechanism science. None of the pathways above change that guidance.
Questions readers commonly ask
Frequently asked questions
What is residual cardiovascular risk?
Does colchicine or an anti-inflammatory drug replace a statin?
Should I ask for clonal hematopoiesis (CHIP) testing?
Can changing my diet lower TMAO and reduce my risk?
Is there a drug available now to lower Lp(a)?
Do GLP-1 medications protect the heart even in people without diabetes?
Sources for editorial verification
The mechanisms and trials named in this article (CANTOS, COLCOT, LoDoCo2, FOURIER, LEADER, SUSTAIN-6, SELECT, PREDIMED, ALL-HEART, FIDELIO-DKD, and the CHIP cohort studies by Jaiswal and colleagues) are established, publicly reported cardiovascular trials and cohort studies. Specific numeric results (hazard ratios, confidence intervals, enrollment sizes) cited in earlier drafts of this article could not be re-verified against a confirmed primary-source link during this revision and should be checked against the original journal publication (NEJM, Lancet, JACC, Circulation, or JAMA, as applicable) before any number is republished or used in a patient-facing claim. No PubMed identifier could be confidently matched to a specific claim during this review, so exact citation links have been removed rather than left pointing to an unverified or possibly mismatched source.